AI MARKET SCANNING

NewAmsterdam Pharma Company NV

📅 Next Catalyst: Nov 11, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Pharmaceuticals Major
AVG HISTORICAL GAP -0.45%
MAX GAP RECORD -3.03%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $NAMS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (BEFORE OPEN) 🔮 UPCOMING 🔒
Aug 12, 2026 Earnings Release 2026-08-12 (BEFORE OPEN)
+1.18%
May 07, 2026 Earnings Release 2026-05-07 (UNDETERMINED)
+0.00%
Feb 18, 2026 Earnings Release 2026-02-18 (UNDETERMINED)
+0.00%
Nov 05, 2025 Earnings Release 2025-11-05 (BEFORE OPEN)
-3.03%
Aug 06, 2025 Earnings Release 2025-08-06 (UNDETERMINED)
+0.00%
May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE)
+0.00%
Feb 26, 2025 Earnings Release 2025-02-26 (UNDETERMINED)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.7%
Bullish Gaps (2)
Bearish Gaps (2)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $NAMS

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 2435m +1.55%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗